key: cord-0851636-qh262shp authors: Yasar, Zehra; Yemisen, Mucahit; Yasar, Huseyin; Ertaş, Aysun; Meric, Kaan; Sahin, Soner title: Can treatment with teicoplanin improve the prognosis of COVID‐19 patients? date: 2021-09-18 journal: Int J Clin Pract DOI: 10.1111/ijcp.14752 sha: 859b81256aeba865063190a9ec887ac7ec1166cf doc_id: 851636 cord_uid: qh262shp AIM: In patients with COVID‐19, no validated efficient treatment has been reported. Herein, we examine the effect of treatment with teicoplanin in hospitalised patients with COVID‐19. METHODS: This retrospective study included 115 hospitalised patients in one medical centre. Fifty‐four patients with laboratory‐confirmed COVID‐19 who received teicoplanin plus standard care were included in the Teicoplanin arm of this study, whereas 61 patients who were treated with standard care (SC) according to the Turkish Health Organization guidelines were included in the control arm. Patients’ baseline characteristics, clinical presentation, treatment and outcomes were compared between the two groups. RESULTS: In this non‐randomised control study, all baseline characteristics were comparable between the two arms and there were no significant differences in the presenting symptoms, comorbidities and clinical outcomes between the two groups. However, the mortality rate was significantly lower in the teicoplanin group than in the control group (1.9% vs 14.8%; P < .05). In addition, no adverse reactions were found in the teicoplanin arm. CONCLUSIONS: Teicoplanin administration is associated significantly with lower mortality in hospitalised patients with COVID‐19 in our study. Further clinical investigations is required to verify the role of teicoplanin in COVID‐19 patients. skin hypoperfusion signs, organ dysfunction such as confusion, kidney and liver tests abnormalities, thrombocytopenia, elevated troponin level and arrhythmia were evaluated for the main intensive care unit (ICU) admission indications according to Turkish Health Organization Guidelines. All of these data were extracted from the electronic medical record. Categorical variables were expressed as absolute frequency and percentage and compared with χ 2 test or Fisher's exact test. Continuous variables were expressed as median and interquartile range (IQR) and compared with Mann-Whitney U and Wilcoxon tests to analyse statistical differences. All the tests were two-sided and a P value < .05 was considered statistically significant. The statistical analysis was carried out using SPSS. 15 This study was approved by the Ethics Committee of Turkey Ministry of Health (2020-05-16T100919. The patients enrolled in the study were aged with a mean of 57. 8 • Teicoplanin administration is associated significantly with lower mortality in hospitalised patients with COVID-19. Therefore, it is important to manage the COVID-19 patients with a safe, cheap and widely available drug, the present findings suggest that teicoplanin can be considered as a first-line treatment for SARS-CoV-2 to prevent disease progression and mortality. to teicoplanin administration. In the SC group, 10 (16.4%) patients were treated with hydroxychloroquine, azithromycin; 41 (67.2%) with hydroxychloroquine, azithromycin and anticoagulant theraphy; 10 (16.4%) with hydroxychloroquine, azithromycin, favipiravir and anticoagulant theraphy. In 12 (19.6%) patients, quinolones or cephalosporins were added according to control secondary infection. Tocilizumab was required for 6 (9.8%) patients in the SC group. On follow-up day, three CRP and D-dimer showed a statistically significant decrease in the Teicoplanin group (CRP; P = .030, D-dimer; P < .001). Comparison of hemato-biochemical parameters, treatment between groups is shown in Table 2 . Thirty-five (64.8%) teicoplanin-treated patients required oxygen inhalation, 14 (25.9%) patients needed non-invasive mechanical ventilation and 16 (29.6%) required admission to an ICU. There were no statistically significant differences between the two groups. On the other hand, the mortality rate was statistically significantly lower in the teicoplanin group than SC (1.9% vs 14.8%; P < .05) ( Table 3 ). This retrospective study showed that it is safe to use teicoplanin in hospitalised patients with COVID-19 infection; moreover, its use was associated with a lower mortality rate. We also found a statistically significant decrease in CRP and D-dimer levels in the teicoplanintreated group on follow-up day 3. We did not observe a significant difference in any other clinical outcomes, including the lengths of the hospital and ICU stays, despite the lower mortality. After infection with SARS-CoV-2, the disease generally progresses within 1 wk of symptom onset because of uncontrolled viral replication in the upper respiratory tract [8] [9] [10] [11] ; this leads to immune anomalies and a cytokine storm. 8 13 Ceccarelli et al investigated the use of teicoplanin in critically ill patients but found that it was not associated with a significant improvement in outcomes. They speculated that the antiviral activity of teicoplanin is likely more effective in the early clinical stages. 14 Ceccarelli et al reported that the mortality and discharge rates of severe COVID-19 in three ICUs were 42.9% and 14.3%, respectively. 7 A recent study by the same authors showed that the crude in-hospital 30-d mortality rate was lower in the teicoplanin-treated group (35.2%) compared with the control group (42.8%), although the difference was not statistically significant. 14 In our study, all patients had moderate or severe disease and the mortality rate was significantly lower in the teicoplanin group. Unlike these two studies, the fact that our patient group consisted of moderate and severe patients may explain the lower mortality rates. Appropriate and rapid management of patients with mild to moderate symptoms is essential to prevent disease progression and mortality. It is important to investigate the utility of teicoplanin in the early stages of COVID-19. Glycopeptide antibiotics were used as antiviral agents for COVID-19, and for empiric treatment of possible superinfections. However, the role of teicoplanin in COVID-19 infection remains under investigation and the agent has not been approved by the FDA. In a previous study, teicoplanin was administered at a dose of 600 mg/d, which usually results in a serum trough concentration >10 mg/L. This trough concentration is regarded as adequate for the treatment of bacterial infection. 7 A recent study reported that the IC50 concentration of teicoplanin in vitro was 1.66 μΜ, which is much lower than the concentration reached in human blood (8.78 μΜ for a daily dose of 400 mg). 13 In our study, teicoplanin was administered at a dose of 400 mg/d. Therefore, the routine dose used for COVID-19 patients can be considered to be 400 mg/d. Ceccarelli et al reported that the peripheral lymphocyte count progressively and significantly improved after treatment. CRP and procalcitonin also showed statistically significant decreases in their study. 7 Similarly, we found that CRP and D-dimer levels were significantly lower in the teicoplanin group on follow-up day 3. Also, we did not observe any adverse events related to teicoplanin administration. This study had several limitations. Because of its retrospective, observational nature, potential differences between the groups might not have been detected because of the small sample size and lack of quantitative evaluation of the viral response. However, considering that the antiviral regimens of the groups were similar, no differences were expected. Another limitation was that disease status at baseline could not be confirmed by PCR in all patients. Nevertheless, all patients presented with symptoms, signs, blood test results and radiological findings compatible with COVID-19. In conclusion, we found that teicoplanin administration was associated with lower mortality in hospitalised patients with COVID-19. It is important to manage COVID-19 patients with a safe, cheap and widely available drug. Our findings suggest that teicoplanin can be considered as a first-line treatment for SARS-CoV-2 to prevent disease progression and mortality. Appropriately designed randomised clinical trials are required to better elucidate the antiviral mechanism of teicoplanin, and its role in the management of COVID-19 patients. Data available on request due to privacy/ethical restrictions. https://orcid.org/0000-0001-5223-4763 Clinical features of patients infected with 2019 novel coronavirus in Wuhan New coronavirus pneumonia diagnosis and treatment plan (trial version 6). National Health Commission of PRC(NHC); 2020 Teicoplanin: an alternative drug for the treatment of COVID-19? Arguments in favour of remdesivir for treating SARS-CoV-2 infections Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV) Teicoplanin potently blocks the cell entry of 2019-nCoV Intensive care COVID-19 study group of Sapienza University Virological assessment of hospitalized patients with COVID-2019 Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models The role of teicoplanin in the treatment of SARS-CoV-2 infection: a retrospective study in critically ill COVID-19 patients (Tei-COVID study) Vademecum per la cura delle persone con malattia da COVID-19. Versione 2.0, 13 marzo 2020 [ Handbook for the care of people with COVID-19 disease. Version 2.0 Can treatment with teicoplanin improve the prognosis of COVID-19 patients?